Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, and Chronic Myeloid Leukemia Treatments.
Molecular taxonomy of myelodysplastic syndromes and its clinical implications
Molecular and clinical presentation of <i>UBA1</i>-mutated myelodysplastic syndromes
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues
Hematopoietic differentiation is characterized by a transient peak of entropy at a single-cell level
<i>Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS</i>
COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects
Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19
Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European <scp>LeukemiaNet</scp>
Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS‐Flow</scp> Cytometry Working Group
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
<i>SF3B1</i>-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
Immune responses during COVID-19 infection
p53 activation during ribosome biogenesis regulates normal erythroid differentiation
Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia
Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
A variant erythroferrone disrupts iron homeostasis in <i>SF3B1</i> -mutated myelodysplastic syndrome
Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis
Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes